“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 09/06/2023
EUR0.17
▲ −0.01 (−3.47%)
Market capitalisation
EUR6m
Quantum Genomics is a Paris-based biotechnology company focused on addressing unmet medical needs.
The global market for cardiovascular drugs is considerable; in 2021 the market for hypertension drugs alone was estimated to be worth c US$13bn. Quantum Genomics has already secured seven licensing deals worldwide (worth up to c US$123m) but has not yet signed an agreement in the key US or EU5 regions. We view the signing of a licensing agreement in these regions as key to maximising the commercial impact of the asset.
Managing Director - Head of Content, Healthcare
Benoît Gueugnon
CFO
Jean-Philippe Milon
CEO
Lionel Ségard
Founder & Chairman
Forecast net debt (€m)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (6.8) | 4.7 | (91.2) |
| Relative | (4.2) | 6.6 | (92.0) |
| 52 week high/low | €4.0/€0.1 |
Following the announcement that results from the Phase III FRESH study, investigating the use of firibastat in treatment-resistant hypertension (TRH) were non-significant versus placebo, Quantum Genomics has terminated a second, longer-term Phase III trial (REFRESH) in TRH and will stop the development of firibastat in cardiology. The company estimates it will have c €11m after the full discontinuation of cardiology development with which to pursue new opportunities to develop new assets. Our estimates and valuation for Quantum Genomics are under review.
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 4.0 | (13.1) | (14.7) | (72.0) | N/A | N/A |
| 2021A | 6.2 | (14.9) | (15.4) | (58.0) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
